Resolian, a drug metabolism and pharmacokinetics expert, has acquired Denali Medpharma, expanding its global bioanalytical presence to include operations in the US, UK, Australia, and China. This strategic move allows seamless method transfers across continents, aiding global therapeutic trials. The acquisition enhances Resolian’s service offerings, adding Denali’s specialized oligo, mRNA, and liposomal analysis to its portfolio. Both companies celebrate the merger, promising enhanced capabilities, innovation, and value to clients worldwide.
Resolian, a global bioanalytical contract research organization (CRO) specializing in drug metabolism and pharmacokinetics for small and large molecules, has acquired Denali Medpharma, a leading China-based bioanalytical CRO. Resolian now has bioanalysis laboratory operations in the U.S., U.K., Australia, and China. The company can initiate a project on four continents and easily transfer validated methods across labs, allowing therapeutic trials to extend to virtually any destination without changing bioanalytical CROs.
“The strategic addition of Denali will significantly enhance our capabilities and strengthen our position in the global market,” said Resolian CEO Patrick Bennett. “Denali’s founders and core scientists are internationally recognized across pharmaceutical research and development analysis and we are particularly excited to add Denali’s oligo, mRNA, and liposomal expertise to Resolian’s portfolio of services. We look forward to leveraging our growing company’s strengths to continue driving innovation and creating lasting value for our clients and stakeholders.”
“The Denali team is thrilled to join Resolian,” said Denali CEO Min Meng, Ph.D. “Denali was founded by a group of U.S.-trained bioanalytical experts in a state-of-the-art lab facility in China to provide exceptional service for domestic and international clients. We look forward to continuing this track record and offering even greater capabilities and trial flexibility as part of Resolian.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Biospace